Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 30.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,393 shares of the pharmaceutical company’s stock after buying an additional 558 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Vertex Pharmaceuticals were worth $1,119,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Telos Capital Management Inc. boosted its holdings in Vertex Pharmaceuticals by 1.6% in the fourth quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock valued at $6,133,000 after purchasing an additional 237 shares during the last quarter. Brookstone Capital Management grew its position in shares of Vertex Pharmaceuticals by 11.1% during the first quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock worth $990,000 after buying an additional 237 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Vertex Pharmaceuticals by 15.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 29,897 shares of the pharmaceutical company’s stock worth $12,497,000 after buying an additional 3,999 shares during the last quarter. Brevan Howard Capital Management LP increased its stake in shares of Vertex Pharmaceuticals by 216.3% in the fourth quarter. Brevan Howard Capital Management LP now owns 4,830 shares of the pharmaceutical company’s stock worth $1,965,000 after buying an additional 3,303 shares during the last quarter. Finally, Greenwood Capital Associates LLC raised its holdings in Vertex Pharmaceuticals by 11.3% in the fourth quarter. Greenwood Capital Associates LLC now owns 25,345 shares of the pharmaceutical company’s stock valued at $10,313,000 after acquiring an additional 2,576 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VRTX has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Piper Sandler boosted their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, July 26th. UBS Group reduced their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Finally, BMO Capital Markets boosted their target price on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Hold” and an average target price of $485.91.

Insider Transactions at Vertex Pharmaceuticals

In other news, CEO Reshma Kewalramani sold 1,565 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the completion of the sale, the chief executive officer now owns 121,374 shares in the company, valued at approximately $55,467,918. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Reshma Kewalramani sold 1,565 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the transaction, the chief executive officer now owns 121,374 shares of the company’s stock, valued at approximately $55,467,918. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce I. Sachs sold 7,073 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at $17,920,000. The disclosure for this sale can be found here. Insiders have sold 55,703 shares of company stock valued at $26,615,855 in the last quarter. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded up $0.56 on Thursday, hitting $472.00. The company had a trading volume of 1,306,905 shares, compared to its average volume of 1,219,359. The company has a market cap of $121.80 billion, a PE ratio of 30.59 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals Incorporated has a 52 week low of $340.83 and a 52 week high of $510.64. The business has a 50-day simple moving average of $480.92 and a 200-day simple moving average of $441.77.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.53 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.